Sanggenol L Enhances Temozolomide Drug Sensitivity by Inhibiting Mitophagy and Inducing Apoptosis Through the Regulation of the TRIM16‐OPTN Axis in Glioblastoma
Advanced Science · 2025
DOI: 10.1002/advs.202502915 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Hongbo Chang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Resource Insects, Medical Research Institute, Southwest University, Chongqing, 400715, China. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Mitophagy, Apoptosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Guangxi Major Science and Technology Project.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most aggressive and lethal form of glioma, with current standard‐of‐care treatments including surgical resection, radiotherapy, and chemotherapy with temozolomide (TMZ). However, therapeutic resistance to TMZ frequently arises, partly attributed to autophagy, as demonstrated by analysis of clinical glioblastoma specimens. Through screening of mulberry metabolites, a bioactive small molecule, Sanggenol L (SL) is identified, which inhibits glioblastoma growth and blocks autophagy flux, thereby markedly enhancing TMZ chemosensitivity when delivered via a liposome‐based system. Mechanistically, SL is found to suppress mitophagy by promoting ubiquitin‐mediated proteasomal degradation of OPTN. Moreover, the first evidence that SL upregulates TRIM16 expression is presented, which acts as an E3 ubiquitin ligase for OPTN degradation in glioblastoma. TRIM16 depletion or OPTN overexpression partially abrogated SL‐induced suppression of autophagy and apoptosis in GBM cells. Collectively, these findings suggest that SL enhances TMZ sensitivity by disrupting autophagy and inducing apoptosis through TRIM16‐mediated OPTN degradation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Resource Insects, Medical Research Institute, Southwest University, Chongqing, 400715, China.
- Jinfeng Laboratory, Chongqing, 401329, China.
- Department of Neurology, the Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
ORCID-Profile: Hongjuan Cui
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Guangxi Major Science and Technology Project
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Chang, H., Hou, J., Hu, X., Hou, N., Xu, M., Du, Y., Xu, J., Wang, Y., Xie, Z., Shi, J., Zhang, Y., & Cui, H. (2025). Sanggenol L Enhances Temozolomide Drug Sensitivity by Inhibiting Mitophagy and Inducing Apoptosis Through the Regulation of the TRIM16‐OPTN Axis in Glioblastoma. Advanced Science. https://doi.org/10.1002/advs.202502915
Vancouver
Chang H, Hou J, Hu X, Hou N, Xu M, Du Y, et al. Sanggenol L Enhances Temozolomide Drug Sensitivity by Inhibiting Mitophagy and Inducing Apoptosis Through the Regulation of the TRIM16‐OPTN Axis in Glioblastoma. Advanced Science. 2025. doi:10.1002/advs.202502915
BibTeX
@article{Chang2025,
author = {Chang, Hongbo and Hou, Jianbing and Hu, Xin and Hou, Nana and Xu, Minghao and Du, Yi and Xu, Jingyang and Wang, Yongzhao and Xie, Zhuohao and Shi, Junbo and Zhang, Yundong and Cui, Hongjuan},
title = {Sanggenol L Enhances Temozolomide Drug Sensitivity by Inhibiting Mitophagy and Inducing Apoptosis Through the Regulation of the TRIM16‐OPTN Axis in Glioblastoma},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202502915}
}
EUVIMED